Global Oral Solid Dosage Contract Manufacturing Market Size is valued at USD 35.6 Bn in 2024 and is predicted to reach USD 63.5 Bn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034.
Oral Solid Dosage Contract Manufacturing are the complexity of new drug compounds will all contribute to the market's expansion. Because they are affordable, easy to produce, and convenient for patients, oral solids are the dosage forms that are most commonly used in the pharmaceutical industry. Oral solids can now attain even better levels of bioavailability while requiring less frequent medication administration because of developments in drug delivery technology, including the distribution of pharmaceuticals and sustained-release formulation. The most fundamental forms of solid dosage forms are tablets and capsules.
To improve patient compliance, businesses are already utilizing cutting-edge technologies to increase the bioavailability of dose forms. Contract manufacturers for oral solid dosage forms launch or improve new products. Increased investments in infrastructure development, plant expansions, and CDMO capabilities to offer fully integrated services will boost the contract development and manufacturing industry over the coming years.
The Oral Solid Dosage Contract Manufacturing market is categorized on the basis of product type, mechanism, and end-user. The product type segment includes tablets, capsules, powders, granules, and others (lozenges, gummies, pastilles, etc.). The mechanism segment includes immediate-release, delayed-release, and controlled-release. By end-user, the market is segmented into large-size companies, medium- & small-size companies, and others (startups & generic pharmaceutical companies).
The tablet and capsule category is expected to hold a major share of the global Oral Solid Dosage Contract Manufacturing market. This can be ascribed to the portability, simplicity in ingesting, good absorption, and medical adherence that various dose forms offer. Due to their expanded capabilities and enormous production capacities, established businesses (with over 10,000 employees) are also projected to hold over 50% of the current and future market in terms of company size.
The market has been divided into three types based on mechanisms: controlled-release, delayed-release, and immediate-release. In 2022, the controlled-release mechanism market category had a maximum revenue share. During the projected period, the segment is also anticipated to increase at the fastest rate. Drug developers can create medications that are kinder to patients while still being effective by altering the pace and/or location at which an API is released. Controlling the release of the API allows for a reduction in the number of dosages needed per day as well as the exclusion of variations in drug plasma levels, which often lead to fewer adverse effects.
With a significant CAGR over the projection period, Asia Pacific is anticipated to keep the quickest rate of growth in the region. Additionally, the region held the most important market share in 2021. With much lower prices, India and China are the APAC region's OSD CMO market leaders. Manufacturing of generic drugs is the second-largest source of revenue in the APAC area due to rising patent expiration rates.
CMOs are also working to achieve ISO accreditation in energy use, quality management, and environmental management. Additionally, while the quantity of warning letters has fallen in developed countries, it has risen in Asia Pacific, and transgressions of cGMP production standards have brought on most recalls. In addition, due to investments made by local businesses and increased FDA drug approval, North America is the second-most lucrative area.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 35.6 Bn |
| Revenue forecast in 2034 | USD 63.5 Bn |
| Growth rate CAGR | CAGR of 6.0% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Product Type, Mechanism, And End-User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Catalent Inc; Lonza Group; Piramal Pharma Solutions; Aenova; Jubilant; Boehringer Ingelheim; AbbVie Contract Manufacturing; Patheon; Recipharm; Next Pharma AB; Siegfried AG; Corden Pharma. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Oral Solid Dosage Contract Manufacturing Market By Product Type Outlook-
Oral Solid Dosage Contract Manufacturing Market By Mechanism Outlook-
Oral Solid Dosage Contract Manufacturing Market By End-user Outlook-
Oral Solid Dosage Contract Manufacturing Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.